Effects of Leejung-tang (理中湯) on MIA-Induced Osteoarthritis Rat

이중탕(理中湯)이 골관절염 유발 생쥐에 미치는 영향

  • Received : 2013.12.17
  • Accepted : 2014.01.03
  • Published : 2014.01.31

Abstract

Objectives This study intends to clarify how Leejung-tang (here in after reffered to LJT) affect Wistar Rat whose osteoarthritis was induced by MIA. Methods Osteoarthritis was induced into rat by injecting MIA in its knee joint. Rats are divided into a total of 4 groups (n=6). Normal group are not treated at all without inducing osteoarthritis whereas control group were induced for osteoarthritis by MIA and oral medicated with 2 ml of physiological saline per day. Positive comparison group (Indomethacin) was injected with MIA and after 7 days, 2 mg/kg of Indomethacin was medicated. Experimental group (LJT) was injected with MIA and after 7 days that was medicated with 23 mg/kg of LJT. Indomethacin and LJT were oral medicated for each substance a total of 4 weeks with one time per day. After experiments (from 1 week after injection of MIA to 4 weeks elapsed), Hind paw weight bearing ability, Functions of liver and kidney, Serum prostaglandin $E_2$, TNF-${\alpha}$, IL-1${\beta}$, IL-6, Osteocalcin, TIMP-1, MMP-9, LTB4 and amount of cartilage were measured and histopathological variations for knee joint structures were observed. Results 1) Hind paw weight bearing ability of LJT administration group was increased but there was no statistical significance. 2) Functions of liver and kidney were not affected. 3) Serum prostaglandin $E_2$, IL-1${\beta}$, Osteocalcin, MMP-9 were significantly decreased and TNF-$\alpha$, IL-6, TIMP-1, LTB4 were also decreased but there were no statistical significance. 4) In H&E staining and Safranin-O staining, there were small histopathological changes in LJT administration group than control group. 5) In micro CT (computed tomography)-arthrography, cartilage destruction was more suppressed in LJT administration group than control group. Conclusions Based on all results mentioned above, Leejung-tang (LJT) is believed to be meaningful for suppressing the progress of osteoarthritis and its treatments because of its anti-inflammatory effects and alleviation of pain with histopathological effective efficacy.

Keywords

Leejung-tang (LJT);Osteoarthritis;MIA-induced osteoarthritis;Cytokine;Indomethacin

References

  1. 한방재활의학과학회. 한방재활의학. 서울:군자출판사. 2011: 84-98.
  2. Hogenmiller MS, Lozada CJ. An update on osteoarthritis therapeutics. Curr Opin Rheumatol. 2006;18:256-60. https://doi.org/10.1097/01.bor.0000218945.96988.0a
  3. 김현아. 퇴행성 관절염의 임상연구. 대한류마티스학회지. 2000;7(3):205-11.
  4. 박동수, 정수현, 김순중, 서일복. 加減小續命湯이 Monosodium Iodoacetate로 유발된 골관절염의 초기변화에 미치는 영향. 한방재활의학과학회지. 2011;21(4):49-65.
  5. 한영규, 박영회, 금동호, 이명종. 加味蒼栢散이 Carrageenan 유발 동물모델 관절염의 소염, 진통, 해열 및 면역에 미치는 영향. 한방재활의학과학회지. 2005;15(1):127-41.
  6. 최재영, 오민석. 甘草附子湯이 Papain으로 유도된 골관절염에 미치는 실험적 연구. 한방재활의학과학회지. 2012; 22(4):37-57.
  7. 윤상구, 박영회, 이명종. 牽牛子가 관절염 유발 흰쥐의 소염 및 해열작용에 미치는 영향. 한방재활의학과학회지. 2003;13(3):63-72.
  8. 조중현, 권오곤, 우창훈, 안희덕. Collagen으로 유발된 마우스의 관절염에 대한 薏苡仁湯 추출물의 억제 효과. 한방재활의학과학회지. 2010;20(1):37-60.
  9. 김덕희. 活絡丹의 Adjuvant 유발 관절염 진행 억제 효과. 세명대학교 대학원. 2009.
  10. 임동욱, 김미연, 송미경, 김지영, 이동헌, 박주연, 부영민, 김호철. 한약복합물 HT008이 흰쥐 관절염 모델에 미치는 효과. 대한본초학회지. 2009;24(4):197-204.
  11. 오진환. 백서의 관절염모델에서 침과 전기침의 통증 억제 효과. 연세대학교 대학원. 2003.
  12. 오춘군. Complete Freund's Adjuvant에 의해 유발된 관절염 백서모델에 있어서 침의 진통효과. 원광대학교 한의학과전문대학원. 2001.
  13. 김환영, 최진봉. 蜂毒약침과 鹿茸약침이 MIA 유도 골관절염 흰쥐에 미치는 영향. 한방재활의학과학회지. 2010;20(1): 61-77.
  14. 김세진. 紫河車약침과 鹿茸약침이 관절연골세포의 자가고사 및 MIA로 유발된 흰쥐의 퇴행성 관절염에 미치는 영향, 동신대학교 한의학과 대학원. 2008.
  15. 김동희, 김성우, 김성훈, 김정범, 맹웅재, 문준전, 박종오, 박종현, 신상우, 안규석, 엄현섭, 이광규, 이선구, 임진석, 전영완, 최정우. 現代傷寒論. 서울:한의문화사. 2007:647.
  16. 노의준, 강한은. 古方類聚. 서울:도서출판 고방. 2009:165.
  17. 李載熙. 圖說韓方診療要方. 원주:의방출판사. 2007:616-7.
  18. 김진호, 한태륜. 재활의학. 서울:군자출판사. 2006:501-24.
  19. 대한정형외과학회. 정형외과학. 제6판. 서울:최신의학사. 2006:253-61.
  20. Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW, Kelly-Hayes M, Wolf PA, Kreger BE, Kannel WB. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health. 1994;84(3):351-8. https://doi.org/10.2105/AJPH.84.3.351
  21. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MM, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778-99. https://doi.org/10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V
  22. 통계청. 장래인구추계(2010-2060). [cited 2011 Dec 8]. Available from: URL: http://kostat.go.kr/portal/korea/kor_ko/5/2/index.board?bmode=read&aSeq=252646.
  23. 진수희. 2009년 국민건강통계. 국민건강영양조사 제4기 3 차년도(2009). 서울:보건복지부 건강정책과. 2010:66.
  24. 김기현. 痺證. 서울:정담출판사. 1993:23-9.
  25. 中國中等醫學敎材編纂委員會. 中醫內科學. 北京:保健新聞社. 1995:682-4.
  26. 王琦 外. 黃帝內經素問今釋. 서울:成輔社. 1983:206.
  27. 蔡仁植. 傷寒論譯詮. 서울:高文社. 1984:9-141.
  28. 張仲景. 金匱要略方論. 臺北:大聯國風出版社. 1950:30-9.
  29. Patrick D. Wall, Ronald Melzack, 통증학 편찬위원회 편. Textbook of pain I. 서울:정담. 2002:575-89.
  30. 한태륜, 방문석. 재활의학 셋째판. 서울:군자출판사. 2009: 905-8.
  31. 이윤종. 골관절염의 치료. 대한내과학회지. 2004;67(5):564-7.
  32. 한성훈. 골관절염의 약물치료. Inje Medical Journal. 2002; 23(4):159-66.
  33. 송영준, 하철원. 골관절염의 치료에서 COX-2 선택적 비스테로이드성 소염진통제의 이용. 대한슬관절학회지. 2009; 21(2):84-92.
  34. 金相贊, 金先熙, 盧昇鉉, 朴宣東, 朴性奎, 徐富一, 徐榮培, 申舜植, 李尙仁, 李長泉, 李棣熙, 朱榮丞, 崔湖榮. 方劑學 서울:永林社. 1999:232-3.
  35. 吉益東洞. 藥徵. 서울:청홍. 2006:105,116,129,203.
  36. 강민희, 정춘식. 人蔘뇌두의 부종 및 관절염에 미치는 효과. 약학논문지. 2003;14:119-25.
  37. 정태용. Inhibitory effect of Korean ginseng extract on type II collagen-induced arthritis. 연세대학교 대학원. 2009.
  38. 최인호. 高麗人蔘의 노화억제에 관한 연구 - 항산화 작용을 중심으로. 경희대학교 대학원. 1982.
  39. 全國韓醫科大學 共同敎材編纂委員會. 本草學. 서울:永林社. 2004:379, 587.
  40. 김은정. 生薑추출물의 항산화 효과에 관한 연구. 성신여자대학교 대학원. 1991.
  41. 유창성. 生薑의 methanol 추출물 중 항산화 물질. 전북대학교 대학원. 1989.
  42. 최성호. 白朮 추출물의 항산화작용에 대한 약리학적 연구. 경희대학교 대학원. 2011.
  43. 김송희, 박용기. 白朮의 콜라겐 유도 관절염 마우스에서의 관절염 개선 효과 연구. 대한본초학회지. 2012;27(3):1-6.
  44. Amagaya S, Sugishita E, Ogihara Y, Ogawa S, Okada K, Aizawa T. Comparative studies of the steroisomers of glycyrrhetinic acid on anti-inflammatory activities. J Pharmacobiodyn. 1984;7:923-8. https://doi.org/10.1248/bpb1978.7.923
  45. Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoyland JA, Brown KK, Hsieh LC, Almstead NG, De B, Natchus MG, Pikul S, Taiwo YO. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis and Cartilage. 2001;9:751-60. https://doi.org/10.1053/joca.2001.0472
  46. Combe R, Bramwell S, Field MJ. The monosodium iodoacetate model of osteoarthritis. Neurosci Lett. 2004; 370(2-3):236-40. https://doi.org/10.1016/j.neulet.2004.08.023
  47. Guzman RE, Evans mg, Bove S, Morenko B, Kilgore K. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol. 2003;31(6):619-24. https://doi.org/10.1080/01926230390241800
  48. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum. 1997; 40(9):1670-9. https://doi.org/10.1002/art.1780400917
  49. 김지영, 김순중, 서일복, 정수현. 附子湯이 Monosodium Iodoacetate로 유발된 골관절염의 초기변화에 미치는 영향. 한방재활의학과학회지. 2011;21(2):87-100.
  50. 김대형, 정수현, 서일복, 김순중. 疎風活血湯이 Monosodium Iodoacetate로 유발한 흰쥐의 골관절염 억제에 미치는 영향. 한방재활의학과학회지. 2011;21(1):57-77.
  51. 안희빈, 김순중, 서일복, 정수현. 二妙散이 흰쥐의 Monosodium Iodoacetate 유발 골관절염에 미치는 영향. 한방재활의학과학회지. 2010;20(3):13-26.
  52. 金垈烔. 加味消炎湯이 Monosodium Iodoacetate로 유발된 골관절염 통증 모델에서 중추신경계 NOS, C-fos, Serotonin 및 Substance P 발현에 미치는 영향. 세명대학교 대학원. 2007.
  53. Shen, Sharett et al. J Am Chem Soc. 1963:488.
  54. Winter CA, Risley EA, Nuss GW. Anti inflammatory and antipyretic activities of indomethacin. J Pharmacol Exptl Therap. 1963:141, 369.
  55. Cryer B, Dubois A. The advent of highly selective inhibitors of cyclooxygenase. A Review Prostaglanins & other Lipid Mediators. 1998;56:341-61. https://doi.org/10.1016/S0090-6980(98)00064-1
  56. Horton JK, Williams AS, Smith-Phillips Z, Martin RC, O'Beime G. Intracellular measurement of prostaglandin E2, Effects of anti-inflammatory drugs on cyclooxygenase activity and prostanoid expression. Analy Biochem. 1999;271:18-28. https://doi.org/10.1006/abio.1999.4118
  57. Chevalier X, Mugnier B, Bouvenot G. Targeted anti-cytokine therapies for osteoarthritis. Bull Acad Natl Med. 2006;190(7):1411-20.
  58. Calich AL, Domiciano DS, Fuller R. Osteoarthritis: can anti-cytokine therapy play a role in treatment? Clin Rheumatol. 2010;29(5):451-5. https://doi.org/10.1007/s10067-009-1352-3
  59. Abbas AK, Lichtman AH. 세포분자면역학. 서울:범문사. 2004:243-88.
  60. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330(6149):662-4. https://doi.org/10.1038/330662a0
  61. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment on rheumatoid arthritis. Lancet. 2007;370(9602):1861-74. https://doi.org/10.1016/S0140-6736(07)60784-3
  62. Vilcek J, Lee TH. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem. 1991;266(12):7313-6.
  63. Hulejova H, Baresova V, Klezl Z, Polanska M, Adam M, Senolt L. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine. 2007;38(3):151-6. https://doi.org/10.1016/j.cyto.2007.06.001
  64. LeGrand A, Fermor B, Fink C, Pisetsky DS, Weinberg JB, Vail TP, Guilak F. Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum. 2001;44(9):2078-83. https://doi.org/10.1002/1529-0131(200109)44:9<2078::AID-ART358>3.0.CO;2-J
  65. Simi T. Inhibition of IL-6, IL-10 Signaling and star activation by inflammatory and stress pathways. J Immunol. 2000;165:5227-37. https://doi.org/10.4049/jimmunol.165.9.5227
  66. Uson J, Balsa A. Dorsa pascal-salcedo: Soluble IL-6 receptor and different arthropathies. J Rheumatol. 1997;24: 2069-75.
  67. Katherine L, Manson terry L, Moor James M. Cytokine level in synovial fluid and serum of patient with juvennile rheumatoid arthritis. J Rheumatol. 1994;21:2359-63.
  68. Delmas PD, Stenner D, Wahner HW, Mann KG, Riggs BL. Increase in serum bone $\gamma$-carboxyglutamic acid protein with aging in women. J Clin Invest. 1983;71:1316. https://doi.org/10.1172/JCI110882
  69. Price PA, Parthermore JG, Deftos LJ. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone Gla-protein in the plasma of normal subjects and patients with bone disease. J Clin Invest. 1980;66:878. https://doi.org/10.1172/JCI109954
  70. Price PA, Otsuka AS, Poser JW, Kristaponis J, Raman N. Characterizaton of $\gamma$-carboxyglutamic acid-containing protein from bone. Proc Nat Acad Sci USA. 1976;73:1447. https://doi.org/10.1073/pnas.73.5.1447
  71. Klein L, Lafferty FW, Person OH, Curtiss PH Jr. Correlation of urinary hydroxyproline, serum alkaline phosphatase, and skeletal calcium turnover. Metab Clin Exp. 1964;13:272. https://doi.org/10.1016/0026-0495(64)90106-4
  72. Duda RJ. O'Brien F, Katzmann JA, Peterson JM, Mann KG, Riggs BL. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab. 1988;66:951. https://doi.org/10.1210/jcem-66-5-951
  73. Shaida A, Kenyon G, Devalia J, Davies RJ, MacDonald TT, Pender SL. Matrix metalloproteinases and their inhibitors in the nasal mucosa of patients with perennial allergic rhinitis. J Allergy Clin Immunol. 2001;108(5):791-6. https://doi.org/10.1067/mai.2001.119024
  74. Watelet JB, Bachert C, Claeys C, Van Cauwenberge P. Matrix metalloproteinases MMP-7, MMP-9 and their tissue inhibitor TIMP-1: expression in chronic sinusitis vs nasal polyposis. Allergy. 2004;59(1):54-60. https://doi.org/10.1046/j.1398-9995.2003.00364.x
  75. 김준모. 흡연이 비용종 상피세포와 섬유아세포에서 MMP-9, TIMP-1, VEGF의 발현에 미치는 영향. 울산대학교 대학원. 2008.
  76. Skiles JW, Gonnella NC, Jeng AY. The design, structure, and therapeutic applicaton of matrix metalloproteinase inhibitors. Curr Med Chem. 2001;8:425-74. https://doi.org/10.2174/0929867013373417
  77. 김광석. 인체 섬유육종세포주 HT1080에서 MMP-9 및 MMP-2 유전자 내재성 발현에 대한 신호전달 기전. 충남대학교 대학원. 2005.
  78. Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinases and oral cancer. Oral Oncol. 1999;35:227-33. https://doi.org/10.1016/S1368-8375(99)00004-4
  79. Ford-hutchinson AW, Bray MA, Doig MV. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Natur. 1980; 286:264-5. https://doi.org/10.1038/286264a0
  80. Roitt I, Brostoff J, Male D. Immunology. 5th ed. London:Mosby. 1998:66-9.